{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:43:44Z","timestamp":1791150224922,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T00:00:00Z","timestamp":1599091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s00520-020-05708-2","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T14:03:58Z","timestamp":1599141838000},"page":"6145-6157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-related adverse events: pulmonary toxicity"],"prefix":"10.1007","volume":"28","author":[{"given":"Vickie R.","family":"Shannon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Blidner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Cooksley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dougan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Glezerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Ginex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Girotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7610-3653","authenticated-orcid":false,"given":"Bernardo L.","family":"Rapoport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,3]]},"reference":[{"key":"5708_CR1","doi-asserted-by":"publisher","first-page":"225937","DOI":"10.1136\/bcr-2018-225937","volume":"2018","author":"N Andruska","year":"2018","unstructured":"Andruska N, Mahapatra L, Hebbard C, Patel P, Paul V (2018) Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy. BMJ Case Rep 2018:225937. https:\/\/doi.org\/10.1136\/bcr-2018-225937","journal-title":"BMJ Case Rep"},{"issue":"10","key":"5708_CR2","first-page":"739","volume":"31","author":"A Balaji","year":"2017","unstructured":"Balaji A, Verde F, Suresh K, Naidoo J (2017) Pneumonitis from anti-PD-1\/ PD-L1 therapy. Oncology (Williston Park) 31(10):739\u2013746 754","journal-title":"Oncology (Williston Park)"},{"key":"5708_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12890-018-0592-x","volume":"18","author":"N Koyama","year":"2018","unstructured":"Koyama N, Iwase O, Nakashima E, Kishida K, Kondo T, Watanabe Y, Takahashi H, Umebayashi Y, Ogawa Y, Miura H (2018) High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review. BMC Pulm Med 18:23. https:\/\/doi.org\/10.1186\/s12890-018-0592-x","journal-title":"BMC Pulm Med"},{"issue":"1","key":"5708_CR4","doi-asserted-by":"publisher","first-page":"1701737","DOI":"10.1183\/13993003.01737-2017","volume":"51","author":"G Louvel","year":"2018","unstructured":"Louvel G, Bahleda R, Ammari S, Le Pechoux C, Levy A, Massard C, Le Pavec J, Champiat S, Deutsch E (2018) Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis? Eur Respir J 51(1):1701737. https:\/\/doi.org\/10.1183\/13993003.01737-2017","journal-title":"Eur Respir J"},{"key":"5708_CR5","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.3389\/fphar.2018.01430","volume":"9","author":"K Ma","year":"2018","unstructured":"Ma K, Lu Y, Jiang S, Tang J, Li X, Zhang Y (2018) The relative risk and incidence of immune checkpoint inhibitors related pneumonitis in patients with advanced cancer: a meta-analysis. Front Pharmacol 9:1430. https:\/\/doi.org\/10.3389\/fphar.2018.01430","journal-title":"Front Pharmacol"},{"issue":"12","key":"5708_CR6","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"M Nishino","year":"2016","unstructured":"Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS (2016) Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol 2(12):1607\u20131616. https:\/\/doi.org\/10.1001\/jamaoncol.2016.2453","journal-title":"JAMA Oncol"},{"issue":"14","key":"5708_CR7","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1200\/JCO.2016.71.0434","volume":"35","author":"M Nishino","year":"2017","unstructured":"Nishino M, Hatabu H (2017) Programmed death-1\/programmed death ligand-1 inhibitor-related pneumonitis and radiographic patterns. J Clin Oncol 35(14):1628\u20131629. https:\/\/doi.org\/10.1200\/JCO.2016.71.0434","journal-title":"J Clin Oncol"},{"issue":"24","key":"5708_CR8","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","volume":"22","author":"M Nishino","year":"2016","unstructured":"Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS (2016) PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22(24):6051\u20136060. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1320","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5708_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/MCP.0000000000000382","volume":"23","author":"VR Shannon","year":"2017","unstructured":"Shannon VR (2017) Pneumotoxicity associated with immune checkpoint inhibitor therapies. Curr Opin Pulm Med 23(4):305\u2013316. https:\/\/doi.org\/10.1097\/MCP.0000000000000382","journal-title":"Curr Opin Pulm Med"},{"key":"5708_CR10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","volume":"4","author":"BC Kolla","year":"2016","unstructured":"Kolla BC, Patel MR (2016) Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. J Immunother Cancer 4:80. https:\/\/doi.org\/10.1186\/s40425-016-0185-2","journal-title":"J Immunother Cancer"},{"issue":"9","key":"5708_CR11","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","volume":"37","author":"A Daxini","year":"2018","unstructured":"Daxini A, Cronin K, Sreih AG (2018) Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol 37(9):2579\u20132584. https:\/\/doi.org\/10.1007\/s10067-018-4177-0","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5708_CR12","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/rheumatology\/kew063","volume":"55","author":"RR van den Brom","year":"2016","unstructured":"van den Brom RR, Abdulahad WH, Rutgers A, Kroesen BJ, Roozendaal C, de Groot DJ, Schroder CP, Hospers GA, Brouwer E (2016) Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition. Rheumatology (Oxford) 55(6):1143\u20131145. https:\/\/doi.org\/10.1093\/rheumatology\/kew063","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"5708_CR13","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1177\/0897190017699762","volume":"31","author":"K Arellano","year":"2018","unstructured":"Arellano K, Mosley JC 3rd, Moore DC (2018) Case report of ipilimumab-induced diffuse, nonnecrotizing granulomatous lymphadenitis and granulomatous vasculitis. J Pharm Pract 31(2):227\u2013229. https:\/\/doi.org\/10.1177\/0897190017699762","journal-title":"J Pharm Pract"},{"issue":"8","key":"5708_CR14","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","volume":"13","author":"I Gkiozos","year":"2018","unstructured":"Gkiozos I, Kopitopoulou A, Kalkanis A, Vamvakaris IN, Judson MA, Syrigos KN (2018) Sarcoidosis-like reactions induced by checkpoint inhibitors. J Thorac Oncol 13(8):1076\u20131082. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.031","journal-title":"J Thorac Oncol"},{"key":"5708_CR15","doi-asserted-by":"publisher","first-page":"216217","DOI":"10.1136\/bcr-2016-216217","volume":"2016","author":"C Kim","year":"2016","unstructured":"Kim C, Gao J, Shannon VR, Siefker-Radtke A (2016) Systemic sarcoidosis first manifesting in a tattoo in the setting of immune checkpoint inhibition. BMJ Case Rep 2016:216217. https:\/\/doi.org\/10.1136\/bcr-2016-216217","journal-title":"BMJ Case Rep"},{"issue":"6","key":"5708_CR16","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1158\/2326-6066.CIR-17-0715","volume":"6","author":"M Nishino","year":"2018","unstructured":"Nishino M, Sholl LM, Awad MM, Hatabu H, Armand P, Hodi FS (2018) Sarcoid-Like Granulomatosis of the lung related to immune-checkpoint inhibitors: distinct clinical and imaging features of a unique immune-related adverse event. Cancer Immunol Res 6(6):630\u2013635. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0715","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"5708_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD (2017) Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35(7):709\u2013717. https:\/\/doi.org\/10.1200\/JCO.2016.68.2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"5708_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S2213-2600(18)30500-9","volume":"7","author":"NB Leighl","year":"2019","unstructured":"Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, Patnaik A, Gubens M, Ramalingam SS, Lubiniecki GM, Zhang J, Piperdi B, Garon EB (2019) Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. Lancet Respir Med 7(4):347\u2013357. https:\/\/doi.org\/10.1016\/S2213-2600(18)30500-9","journal-title":"Lancet Respir Med"},{"issue":"8","key":"5708_CR19","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1158\/1535-7163.MCT-17-0155","volume":"16","author":"S Zhang","year":"2017","unstructured":"Zhang S, Liang F, Zhu J, Chen Q (2017) Risk of pneumonitis associated with programmed cell death 1 inhibitors in cancer patients: a meta-analysis. Mol Cancer Ther 16(8):1588\u20131595. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0155","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"5708_CR20","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1634\/theoncologist.2016-0419","volume":"22","author":"TF Nishijima","year":"2017","unstructured":"Nishijima TF, Shachar SS, Nyrop KA, Muss HB (2017) Safety and tolerability of PD-1\/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: a meta-analysis. Oncologist 22(4):470\u2013479. https:\/\/doi.org\/10.1634\/theoncologist.2016-0419","journal-title":"Oncologist"},{"issue":"7","key":"5708_CR21","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengelov L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15(7):700\u2013712. https:\/\/doi.org\/10.1016\/S1470-2045(14)70189-5","journal-title":"Lancet Oncol"},{"issue":"2","key":"5708_CR22","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"M Khunger","year":"2017","unstructured":"Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V (2017) Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer: a systematic review and meta-analysis of trials. Chest 152(2):271\u2013281. https:\/\/doi.org\/10.1016\/j.chest.2017.04.177","journal-title":"Chest"},{"issue":"21","key":"5708_CR23","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, Salama AK, Taylor M, Ott PA, Rollin LM, Horak C, Gagnier P, Wolchok JD, Hodi FS (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006\u20132017. https:\/\/doi.org\/10.1056\/NEJMoa1414428","journal-title":"N Engl J Med"},{"issue":"4","key":"5708_CR24","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"5708_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","volume":"45","author":"TK Eigentler","year":"2016","unstructured":"Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grunwald V, Kahler KC, Loquai C, Reinmuth N, Steins M, Zimmer L, Sendl A, Gutzmer R (2016) Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 45:7\u201318. https:\/\/doi.org\/10.1016\/j.ctrv.2016.02.003","journal-title":"Cancer Treat Rev"},{"key":"5708_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J, Bahr O, Eigentler TK, Grimm MO, Grunwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R (2017) Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36\u201349. https:\/\/doi.org\/10.1016\/j.ctrv.2017.05.003","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"5708_CR27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B (2016) PD-1 blockade expands intratumoral memory t cells. Cancer Immunol Res 4(3):194\u2013203. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0210","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"5708_CR28","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem JB, Brennan DJ, Knolhoff BL, Belt BA, Zhu Y, Sanford DE, Belaygorod L, Carpenter D, Collins L, Piwnica-Worms D, Hewitt S, Udupi GM, Gallagher WM, Wegner C, West BL, Wang-Gillam A, Goedegebuure P, Linehan DC, DeNardo DG (2013) Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res 73(3):1128\u20131141. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2731","journal-title":"Cancer Res"},{"issue":"7655","key":"5708_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL (2017) PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545(7655):495\u2013499. https:\/\/doi.org\/10.1038\/nature22396","journal-title":"Nature"},{"issue":"2","key":"5708_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/cncr.31043","volume":"124","author":"RN Pillai","year":"2018","unstructured":"Pillai RN, Behera M, Owonikoko TK, Kamphorst AO, Pakkala S, Belani CP, Khuri FR, Ahmed R, Ramalingam SS (2018) Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer 124(2):271\u2013277. https:\/\/doi.org\/10.1002\/cncr.31043","journal-title":"Cancer"},{"key":"5708_CR31","doi-asserted-by":"publisher","first-page":"vi379","DOI":"10.1093\/annonc\/mdw379.01","volume":"27","author":"PA Ascierto","year":"2016","unstructured":"Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance Fernandez AM, Schmidt H, Lebbe C, Bastholt L, Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Hennicken D, Qureshi A, Maio M (2016) Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IP) at 3 mg\/kg vs 10 mg\/kg in patients with metastatic melanoma (MEL). Ann Oncol 27:vi379","journal-title":"Ann Oncol"},{"issue":"21","key":"5708_CR32","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, Carcereny E, Ahn MJ, Felip E, Lee JS, Hellmann MD, Hamid O, Goldman JW, Soria JC, Dolled-Filhart M, Rutledge RZ, Zhang J, Lunceford JK, Rangwala R, Lubiniecki GM, Roach C, Emancipator K, Gandhi L, KEYNOTE-001 Investigators (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028. https:\/\/doi.org\/10.1056\/NEJMoa1501824","journal-title":"N Engl J Med"},{"issue":"1","key":"5708_CR33","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s40425-019-0583-3","volume":"7","author":"JD Schoenfeld","year":"2019","unstructured":"Schoenfeld JD, Nishino M, Severgnini M, Manos M, Mak RH, Hodi FS (2019) Pneumonitis resulting from radiation and immune checkpoint blockade illustrates characteristic clinical, radiologic and circulating biomarker features. J Immunother Cancer 7(1):112. https:\/\/doi.org\/10.1186\/s40425-019-0583-3","journal-title":"J Immunother Cancer"},{"issue":"4","key":"5708_CR34","doi-asserted-by":"publisher","first-page":"e470","DOI":"10.1016\/j.cllc.2019.02.018","volume":"20","author":"KR Voong","year":"2019","unstructured":"Voong KR, Hazell SZ, Fu W, Hu C, Lin CT, Ding K, Suresh K, Hayman J, Hales RK, Alfaifi S, Marrone KA, Levy B, Hann CL, Ettinger DS, Feliciano JL, Peterson V, Kelly RJ, Brahmer JR, Forde PM, Naidoo J (2019) Relationship between prior radiotherapy and checkpoint-inhibitor pneumonitis in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 20(4):e470\u2013e479. https:\/\/doi.org\/10.1016\/j.cllc.2019.02.018","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"5708_CR35","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","volume":"50","author":"M Delaunay","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Perol M, Campana M, Gautschi O, Fruh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prevot G, Milia J, Mazieres J (2017) Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 50(2):1700050. https:\/\/doi.org\/10.1183\/13993003.00050-2017","journal-title":"Eur Respir J"},{"issue":"2","key":"5708_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/L18-0209","volume":"169","author":"N Abdel-Wahab","year":"2018","unstructured":"Abdel-Wahab N, Shah M, Lopez-Olivo MA, Suarez-Almazor ME (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med 169(2):133\u2013134. https:\/\/doi.org\/10.7326\/L18-0209","journal-title":"Ann Intern Med"},{"issue":"2","key":"5708_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.7326\/L18-0208","volume":"169","author":"Y Oshima","year":"2018","unstructured":"Oshima Y, Hagino N, Hara M, Ohfuji T (2018) Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease. Ann Intern Med 169(2):133. https:\/\/doi.org\/10.7326\/L18-0208","journal-title":"Ann Intern Med"},{"issue":"4","key":"5708_CR38","first-page":"190","volume":"32","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, Beckermann KE, Wang DY (2018) Immune checkpoint inhibitor therapy in patients with autoimmune disease. Oncology (Williston Park) 32(4):190\u2013194","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"5708_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, Tariq MJ, Durer S, Durer C, Russ A, Parr NNC, Baig Z, Sagar F, Ali Z, McBride A, Anwer F (2019) Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transplant 25(1):94\u201399. https:\/\/doi.org\/10.1016\/j.bbmt.2018.08.028","journal-title":"Biol Blood Marrow Transplant"},{"key":"5708_CR40","doi-asserted-by":"publisher","first-page":"107815521774306","DOI":"10.1177\/1078155217743069","volume":"25","author":"A Jim\u00e9nez-Ubieto","year":"2017","unstructured":"Jim\u00e9nez-Ubieto A, Rodriguez A, Martinez S\u00e1nchez P, G\u00f3mez A, Rodriguez Y, Carre\u00f1o-Tarragona G, Martinez-L\u00f3pez J, Grande C (2017) Fatal graft-versus-host disease after allogeneic stem cell transplantation in a patient recently exposed to nivolumab. J Oncol Pharm Pract 25:1078155217743069\u20131078155217743506. https:\/\/doi.org\/10.1177\/1078155217743069","journal-title":"J Oncol Pharm Pract"},{"issue":"5","key":"5708_CR41","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/14737140.2019.1589374","volume":"19","author":"JP Bewersdorf","year":"2019","unstructured":"Bewersdorf JP, Stahl M, Zeidan AM (2019) Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Rev Anticancer Ther 19(5):393\u2013404. https:\/\/doi.org\/10.1080\/14737140.2019.1589374","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"5708_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/imm.12788","volume":"152","author":"T Jelinek","year":"2017","unstructured":"Jelinek T, Mihalyova J, Kascak M, Duras J, Hajek R (2017) PD-1\/PD-L1 inhibitors in haematological malignancies: update 2017. Immunology 152(3):357\u2013371. https:\/\/doi.org\/10.1111\/imm.12788","journal-title":"Immunology"},{"issue":"9","key":"5708_CR43","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Shipp M, Zinzani PL, Timmerman JM, Ansell S, Armand P, Fanale M, Ratanatharathorn V, Kuruvilla J, Cohen JB, Collins G, Savage KJ, Trneny M, Kato K, Farsaci B, Parker SM, Rodig S, Roemer MG, Ligon AH, Engert A (2016) Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 17(9):1283\u20131294. https:\/\/doi.org\/10.1016\/S1470-2045(16)30167-X","journal-title":"Lancet Oncol"},{"issue":"10088","key":"5708_CR44","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling THR, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 389(10088):2492\u20132502. https:\/\/doi.org\/10.1016\/S0140-6736(17)31046-2","journal-title":"Lancet"},{"issue":"11","key":"5708_CR45","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/cncr.30642","volume":"123","author":"DB Johnson","year":"2017","unstructured":"Johnson DB, Sullivan RJ, Menzies AM (2017) Immune checkpoint inhibitors in challenging populations. Cancer 123(11):1904\u20131911. https:\/\/doi.org\/10.1002\/cncr.30642","journal-title":"Cancer"},{"issue":"6","key":"5708_CR46","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-019-02321-z","volume":"68","author":"KL Kehl","year":"2019","unstructured":"Kehl KL, Yang S, Awad MM, Palmer N, Kohane IS, Schrag D (2019) Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer. Cancer Immunol Immunother 68(6):917\u2013926. https:\/\/doi.org\/10.1007\/s00262-019-02321-z","journal-title":"Cancer Immunol Immunother"},{"issue":"17","key":"5708_CR47","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1200\/JCO.2011.39.3298","volume":"30","author":"G Berthod","year":"2012","unstructured":"Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O (2012) Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol 30(17):e156\u2013e159. https:\/\/doi.org\/10.1200\/JCO.2011.39.3298","journal-title":"J Clin Oncol"},{"issue":"3","key":"5708_CR48","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1148\/radiology.201.3.8939234","volume":"201","author":"M Kaneko","year":"1996","unstructured":"Kaneko M, Eguchi K, Ohmatsu H, Kakinuma R, Naruke T, Suemasu K, Moriyama N (1996) Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography. Radiology 201(3):798\u2013802. https:\/\/doi.org\/10.1148\/radiology.201.3.8939234","journal-title":"Radiology"},{"issue":"1","key":"5708_CR49","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1148\/radiology.179.1.2006262","volume":"179","author":"P Grenier","year":"1991","unstructured":"Grenier P, Valeyre D, Cluzel P, Brauner MW, Lenoir S, Chastang C (1991) Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology 179(1):123\u2013132. https:\/\/doi.org\/10.1148\/radiology.179.1.2006262","journal-title":"Radiology"},{"issue":"4","key":"5708_CR50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1158\/2326-6066.CIR-15-0267","volume":"4","author":"M Nishino","year":"2016","unstructured":"Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, Hatabu H, Janne PA, Hodi FS, Awad MM (2016) Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res 4(4):289\u2013293. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0267","journal-title":"Cancer Immunol Res"},{"key":"5708_CR51","doi-asserted-by":"publisher","first-page":"CD005590","DOI":"10.1002\/14651858.CD005590.pub3","volume":"10","author":"A Stern","year":"2014","unstructured":"Stern A, Green H, Paul M, Vidal L, Leibovici L (2014) Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 10:CD005590. https:\/\/doi.org\/10.1002\/14651858.CD005590.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"5708_CR52","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.4065\/82.9.1052","volume":"82","author":"H Green","year":"2007","unstructured":"Green H, Paul M, Vidal L, Leibovici L (2007) Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 82(9):1052\u20131059. https:\/\/doi.org\/10.4065\/82.9.1052","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"5708_CR53","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1136\/annrheumdis-2017-211796","volume":"77","author":"JW Park","year":"2018","unstructured":"Park JW, Curtis JR, Moon J, Song YW, Kim S, Lee EB (2018) Prophylactic effect of trimethoprim-sulfamethoxazole for pneumocystis pneumonia in patients with rheumatic diseases exposed to prolonged high-dose glucocorticoids. Ann Rheum Dis 77(5):644\u2013649. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211796","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5708_CR54","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4065\/71.1.5","volume":"71","author":"SH Yale","year":"1996","unstructured":"Yale SH, Limper AH (1996) Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 71(1):5\u201313. https:\/\/doi.org\/10.4065\/71.1.5","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"5708_CR55","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4065\/71.1.102","volume":"71","author":"KA Sepkowitz","year":"1996","unstructured":"Sepkowitz KA (1996) Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome: who should receive prophylaxis? Mayo Clin Proc 71(1):102\u2013103. https:\/\/doi.org\/10.4065\/71.1.102","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"5708_CR56","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1001\/archinte.1995.00430110015002","volume":"155","author":"KA Sepkowitz","year":"1995","unstructured":"Sepkowitz KA, Brown AE, Armstrong D (1995) Pneumocystis carinii pneumonia without acquired immunodeficiency syndrome. More patients, same risk. Arch Intern Med 155(11):1125\u20131128. https:\/\/doi.org\/10.1001\/archinte.1995.00430110015002","journal-title":"Arch Intern Med"},{"issue":"4","key":"5708_CR57","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1517\/14740338.2015.1009036","volume":"14","author":"G Murdaca","year":"2015","unstructured":"Murdaca G, Spano F, Contatore M, Guastalla A, Penza E, Magnani O, Puppo F (2015) Infection risk associated with anti-TNF-alpha agents: a review. Expert Opin Drug Saf 14(4):571\u2013582. https:\/\/doi.org\/10.1517\/14740338.2015.1009036","journal-title":"Expert Opin Drug Saf"},{"issue":"12","key":"5708_CR58","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1080\/14787210.2018.1544490","volume":"16","author":"M Fernandez-Ruiz","year":"2018","unstructured":"Fernandez-Ruiz M, Aguado JM (2018) Risk of infection associated with anti-TNF-alpha therapy. Expert Rev Anti-Infect Ther 16(12):939\u2013956. https:\/\/doi.org\/10.1080\/14787210.2018.1544490","journal-title":"Expert Rev Anti-Infect Ther"},{"issue":"1","key":"5708_CR59","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS (2017) Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer 5(1):95. https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J Immunother Cancer"},{"key":"5708_CR60","doi-asserted-by":"publisher","first-page":"100834","DOI":"10.1016\/j.rmcr.2019.100834","volume":"27","author":"CR Petri","year":"2019","unstructured":"Petri CR, Patell R, Batalini F, Rangachari D, Hallowell RW (2019) Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: case report and review of the literature. Respir Med Case Rep 27:100834. https:\/\/doi.org\/10.1016\/j.rmcr.2019.100834","journal-title":"Respir Med Case Rep"},{"issue":"22 Pt 1","key":"5708_CR61","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","volume":"13","author":"SG Downey","year":"2007","unstructured":"Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13(22 Pt 1):6681\u20136688. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0187","journal-title":"Clin Cancer Res"},{"issue":"10","key":"5708_CR62","doi-asserted-by":"publisher","first-page":"e1040218","DOI":"10.1080\/2162402X.2015.1040218","volume":"4","author":"E Arriola","year":"2015","unstructured":"Arriola E, Wheater M, Krishnan R, Smart J, Foria V, Ottensmeier C (2015) Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control. Oncoimmunology 4(10):e1040218. https:\/\/doi.org\/10.1080\/2162402X.2015.1040218","journal-title":"Oncoimmunology"},{"key":"5708_CR63","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","volume":"6","author":"FC Santini","year":"2018","unstructured":"Santini FC, Rizvi H, Plodkowski AJ, Ni A, Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF, Long NM, Kris MG, Rudin CM, Chaft JE, Hellmann MD (2018) Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC. Cancer Immunol Res 6:1093\u20131099. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0755","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"5708_CR64","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1634\/theoncologist.2018-0352","volume":"24","author":"N Asher","year":"2019","unstructured":"Asher N, Marom EM, Ben-Betzalel G, Baruch EN, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G (2019) Recurrent pneumonitis in patients with melanoma treated with immune checkpoint inhibitors. Oncologist 24(5):640\u2013647. https:\/\/doi.org\/10.1634\/theoncologist.2018-0352","journal-title":"Oncologist"},{"issue":"1","key":"5708_CR65","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","volume":"29","author":"MH Pollack","year":"2018","unstructured":"Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN (2018) Safety of resuming anti-PD-1 in patients with immune-related adverse events (IrAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol 29(1):250\u2013255. https:\/\/doi.org\/10.1093\/annonc\/mdx642","journal-title":"Ann Oncol"},{"issue":"12","key":"5708_CR66","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, Rathmell WK, Ancell KK, Balko JM, Bowman C, Davis EJ, Chism DD, Horn L, Long GV, Carlino MS, Lebrun-Vignes B, Eroglu Z, Hassel JC, Menzies AM, Sosman JA, Sullivan RJ, Moslehi JJ, Johnson DB (2018) Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 4(12):1721\u20131728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923","journal-title":"JAMA Oncol"},{"key":"5708_CR67","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","volume":"4","author":"JE Reuss","year":"2016","unstructured":"Reuss JE, Kunk PR, Stowman AM, Gru AA, Slingluff CL Jr, Gaughan EM (2016) Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. J Immunother Cancer 4:94. https:\/\/doi.org\/10.1186\/s40425-016-0199-9","journal-title":"J Immunother Cancer"},{"issue":"10","key":"5708_CR68","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, Nishino M (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3(10):1185\u20131192. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0102","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"5708_CR69","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1164\/rccm.201507-1499OC","volume":"193","author":"J Ramstein","year":"2016","unstructured":"Ramstein J, Broos CE, Simpson LJ, Ansel KM, Sun SA, Ho ME, Woodruff PG, Bhakta NR, Christian L, Nguyen CP, Antalek BJ, Benn BS, Hendriks RW, van den Blink B, Kool M, Koth LL (2016) IFN-gamma-producing T-helper 17.1 cells are increased in sarcoidosis and are more prevalent than T-helper type 1 cells. Am J Respir Crit Care Med 193(11):1281\u20131291. https:\/\/doi.org\/10.1164\/rccm.201507-1499OC","journal-title":"Am J Respir Crit Care Med"},{"key":"5708_CR70","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1479-5876-7-35","volume":"7","author":"E von Euw","year":"2009","unstructured":"von Euw E, Chodon T, Attar N, Jalil J, Koya RC, Comin-Anduix B, Ribas A (2009) CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 7:35. https:\/\/doi.org\/10.1186\/1479-5876-7-35","journal-title":"J Transl Med"},{"issue":"55","key":"5708_CR71","doi-asserted-by":"publisher","first-page":"30587","DOI":"10.18632\/oncotarget.25743","volume":"9","author":"K Tanaka","year":"2018","unstructured":"Tanaka K, Yanagihara T, Ikematsu Y, Inoue H, Ota K, Kashiwagi E, Suzuki K, Hamada N, Takeuchi A, Tatsugami K, Eto M, Ijichi K, Oda Y, Otsubo K, Yoneshima Y, Iwama E, Nakanishi Y, Okamoto I (2018) Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. Oncotarget 9(55):30587\u201330593. https:\/\/doi.org\/10.18632\/oncotarget.25743","journal-title":"Oncotarget"},{"issue":"5","key":"5708_CR72","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.currproblcancer.2019.01.001","volume":"43","author":"SA Atallah-Yunes","year":"2019","unstructured":"Atallah-Yunes SA, Kadado AJ, Soe MH (2019) Pericardial effusion due to pembrolizumab-induced immunotoxicity: a case report and literature review. Curr Probl Cancer 43(5):504\u2013510. https:\/\/doi.org\/10.1016\/j.currproblcancer.2019.01.001","journal-title":"Curr Probl Cancer"},{"key":"5708_CR73","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000447053","volume":"136","author":"I Kushnir","year":"2017","unstructured":"Kushnir I, Wolf I (2017) Nivolumab-induced pericardial tamponade: a case report and discussion. Cardiology 136:49\u201351. https:\/\/doi.org\/10.1159\/000447053","journal-title":"Cardiology"},{"key":"5708_CR74","doi-asserted-by":"publisher","first-page":"e717","DOI":"10.1016\/j.cllc.2018.05.010","volume":"19","author":"A Vittorio","year":"2018","unstructured":"Vittorio A, Sharma R, Siejka D, Bhattarai K, Hardikar A (2018) Recurrent pericardial effusion while receiving nivolumab for metastatic lung adenocarcinoma: case report and review of the literature. Clin Lung Cancer 19:e717\u2013e720. https:\/\/doi.org\/10.1016\/j.cllc.2018.05.010","journal-title":"Clin Lung Cancer"},{"key":"5708_CR75","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3389\/fonc.2019.00004","volume":"9","author":"M Yamasaki","year":"2019","unstructured":"Yamasaki M, Daido W, Saito N, Funaishi K, Okada T, Kawamoto K, Matsumoto Y, Matsumoto N, Taniwaki M, Ohashi N, Hattori N (2019) Pericardial effusion with tamponade in lung cancer patients during treatment with nivolumab: a report of two cases. Front Oncol 9:4. https:\/\/doi.org\/10.3389\/fonc.2019.00004","journal-title":"Front Oncol"},{"key":"5708_CR76","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","volume":"21","author":"MC Garassino","year":"2020","unstructured":"Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, Baena J, Banna G, Berardi R, Bettini AC, Bria E, Brighenti M, Cadranel J, De Toma A, Chini C, Cortellini A, Felip E, Finocchiaro G, Garrido P, Genova C, Giusti R, Gregorc V, Grossi F, Grosso F, Intagliata S, La Verde N, Liu SV, Mazieres J, Mercadante E, Michielin O, Minuti G, Moro-Sibilot D, Pasello G, Passaro A, Scotti V, Solli P, Stroppa E, Tiseo M, Viscardi G, Voltolini L, Wu YL, Zai S, Pancaldi V, Dingemans AM, Van Meerbeeck J, Barlesi F, Wakelee H, Peters S, Horn L (2020) COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 21:914\u2013922","journal-title":"Lancet Oncol"},{"key":"5708_CR77","doi-asserted-by":"crossref","unstructured":"Russano M, Citarella F, Napolitano A, Dell\u2019Aquila E, Cortellini A, Pantano F, Vincenzi B, Tonini G, Santini D (2020) COVID-19 pneumonia and immune-related pneumonitis: critical issues on differential diagnosis, potential interactions, and management. Expert Opin Biol Ther:1\u20135","DOI":"10.1080\/14712598.2020.1789097"},{"key":"5708_CR78","doi-asserted-by":"publisher","first-page":"e000984","DOI":"10.1136\/jitc-2020-000984","volume":"8","author":"J Naidoo","year":"2020","unstructured":"Naidoo J, Reuss JE, Suresh K, Feller-Kopman D, Forde PM, Mehta Steinke S, Rock C, Johnson DB, Nishino M, Brahmer JR (2020) Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. J Immunother Cancer 8:e000984","journal-title":"J Immunother Cancer"},{"key":"5708_CR79","doi-asserted-by":"crossref","unstructured":"Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ (2020) Dexamethasone in hospitalized patients with covid-19 - preliminary report. N Engl J Med","DOI":"10.1101\/2020.06.22.20137273"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05708-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05708-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05708-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T06:36:25Z","timestamp":1744180585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05708-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":79,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5708"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05708-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"24 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"AB, RA, JC, TC, PG, DG, RAG, and VRS have no conflict of interest to declare. MD reports grants from Novartis, other (SAB) from Neoleukin Therapeutics, personal fees from Partner Therapeutics, personal fees from Tillotts Pharma, and grants from Genentech, outside the submitted work. MG reports consultant work with Bristol Myers Squibb (BMS), and AstraZeneca, outside the submitted work. IG reports other (Stock Ownership) from Pfizer Inc. and personal fees from CytomX Inc, outside the submitted work. DBJ reports other (advisory board) from Array Biopharma, grants and other (advisory board) from BMS, other (advisory board) from Jansen, grants from Incyte, other (advisory board) from Merck, and other (advisory board) from Novartis, outside the submitted work. In addition, DBJ has a patent Co-inventor on use of CTLA-4 agonist for IAEs pending. BLR reports personal fees and other (advisory board) from Merck and Co, grants, personal fees, and other (advisory board) from BMS, grants, personal fees, and other (advisory board) from Roche South Africa, and personal fees and other (advisory board) from AstraZeneca, during the conduct of the study. MSA reports personal fees from Gilead, grants from Pfizer, and personal fees from Abbvie, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}